PharmaDerm Launches CUTIVATE(R) Lotion

ATLANTA, Oct. 17 /PRNewswire/ -- PharmaDerm today announced the official launch of CUTIVATE (fluticasone propionate) Lotion, 0.05%, the only mid- potency steroid lotion approved for patients one year of age and older.

This newest entry into the market offers dermatologists a patent-protected mid-potency lotion for their patients’ skincare needs. The new CUTIVATE Lotion treats atopic dermatitis with an excellent safety profile that includes a low potential to suppress HPA-axis function, even when used under exaggerated conditions(1). Also, CUTIVATE Lotion offers patients an emollient- rich formulation that relieves symptoms with just once-a-day dosing.

“We are very excited to launch the new CUTIVATE Lotion and to provide dermatologists with a unique mid-potency lotion for their patients’ needs,” said Malcolm McCoy, vice president of sales and marketing at PharmaDerm. “CUTIVATE Lotion is the only steroid lotion of its kind approved for patients one year of age and older, providing dermatologists with an effective atopic dermatitis treatment for adult and pediatric patients alike.”

The launch of CUTIVATE Lotion comes on the heels of PharmaDerm’s recent acquisition of the prescription dermatology line of GlaxoSmithKline Consumer Healthcare, a division of GlaxoSmithKline Corporation. As part of the acquisition, PharmaDerm will manufacture and market the former GSK products, including ACLOVATE(R) (alclometasone dipropionate), CUTIVATE(R) (fluticasone propionate), EMGEL(R) (erythromycin), OXISTAT(R) (oxiconazole nitrate), and TEMOVATE(R) (clobetasol propionate).

Available by prescription, CUTIVATE Lotion comes in a 60 mL bottle.

About PharmaDerm

PharmaDerm, headquartered in Atlanta, GA and a division of ALTANA Inc., is a specialty pharmaceutical manufacturer of topical dermatological prescription products. The company is dedicated to becoming a true innovator in the field of dermatology: to finding new therapies for skin diseases, to giving dermatologists and patients greater access to existing therapies, and to providing a network of resources and expertise to the field of dermatology. For more information on PharmaDerm, please visit the company online at http://www.pharmaderm.com .

Not for ophthalmic, oral or intravaginal use, or for use by patients with a hypersensitivity to any of its components. In clinical studies, drug-related side effects following the use of CUTIVATE Lotion consisted primarily of localized burning or itching, and were usually mild and self-limiting. No skin atrophy, changes in pigmentation, or evidence of HPA-axis suppression were observed following the use of CUTIVATE Lotion in these studies. Adrenal suppression has been observed in studies with other fluticasone propionate topical formulations.

(1) Friedlander SF, Herbert A, Allen DB. Further evidence of safety of topical fluticasone propionate (FP): Under exaggerated conditions of use, a new emulsion preparation has no effect on HPA-axis function. Poster presented at: Annual Meeting of the American Dermatology; February 23, 2005; New Orleans, LA. See product packaging inserts for full Prescribing Information.

PharmaDerm

CONTACT: Rose Raus of The Robin Shepherd Group, +1-770-295-2314, ext. 104,or rraus@trsg.net, for PharmaDerm